Search
The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read moreThe interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical manifestations
The EHA Specialized Working Group (SWG) on Thrombocytopenias and Platelet Function Disorders and the EHA-SWG on Bleeding and Thrombosis are pleased to collaborate on a recent free webinar: "The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical…
Read moreEHA-ASH TRTH Joint Oversight Committee
Current committee members
Janis Abkowitz
David Bodine
Chiara Bonini
Ruud Delwel
Mary Dinauer
Terry Fry
Jessica Okosun
Kostas Stamatopoulos
AimTo develop, in collaboration with ASH, translational researchers in Europe and beyond by running the TRTH program while maintaining quality of the program elements by choosing and guiding the faculty…
Scientific Program Committee, EHA2025 Congress
Current committee members
Martin Dreyling, Germany (Chair)
Brian Huntly, United Kingdom (Past Chair)
Meritxell Alberich Jordà, Czechia (Chair elect)
Paolo Corradini, Italy (Local representative)
Gabriela Baerlocher, Switzerland
Valentine Brousse, France
Mattia D'Agostino, Italy
Mariane de Montalembert, France
Jordi Esteve, Spain
Thierry Facon, France
Thoas Fioretos, Sweden
Krzystof Giannopoulos, Poland
Shahram Kordasti, United Kingdom
Georg…
PRESS RELEASE: Cyprus Presidency promotes win-win on health and competitiveness
The report, “Building an Open Innovation ecosystem in Europe for healthcare”, will be launched at a press conference in the European Parliament in Brussels on 29 November, 2012.
Read moreProfessor Degos awarded at the 17th Congress of EHA in Amsterdam
Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.
Read more